Century Therapeutics, Inc. 8K

Century Therapeutics furnished an investor presentation describing its cell therapy pipeline, preclinical data, funding runway supported by a $135 million PIPE, and key upcoming milestones for CNTY-813 and CNTY-308.

Century Therapeutics, Inc. furnished an investor presentation (Exhibit 99.2) outlining its strategy of advancing curative cell-engineered medicines, highlighting its CNTY-813 iPSC-derived, Allo-Evasion 5.0–engineered islet replacement therapy for type 1 diabetes and CNTY-308 iPSC-derived CAR-iT program for B‑cell–mediated autoimmune diseases, along with extensive preclinical data, manufacturing capabilities, and platform technology. The presentation discloses that the company completed an oversubscribed $135 million PIPE financing in early 2026, which it expects will fund operations into the first quarter of 2029, and sets out key anticipated milestones including a CNTY-813 oral presentation at EASD 2026, an IND submission for CNTY-813 expected in the fourth quarter of 2026, initial clinical entry for CNTY-308 in 2026, and first CNTY-813 clinical data expected in the second half of 2027.

Filing Facts

CIK

1850119

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-094533

Alert Tier

5